Literature DB >> 7900744

Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms.

M F Gadallah1, M Lynn, J Work.   

Abstract

High-dose intravenous mannitol infusion in various clinical settings may result in acute renal failure (ARF). This form of ARF is characteristically anuric and follows a distinctive clinical course. Most importantly, it occurs only after high doses of mannitol (> 200 g/day or cumulative dose of > 400 g in 48 hours), but not at lower doses. It appears that a low dose of mannitol acts as a renal vasodilator while high-dose mannitol is renal vasoconstrictor. Mannitol-induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure. This is a report of a case of anuric ARF after high-dose mannitol infusion for treatment of narrow-angle glaucoma that readily responded to acute hemodialysis. The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of mannitol nephrotoxicity are discussed. Hemodialysis should be performed for rapid reversal of mannitol-induced ARF. Patients not treated with hemodialysis have increased morbidity and significant prolongation of their hospital course.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7900744     DOI: 10.1097/00000441-199504000-00006

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  12 in total

1.  The combined use of edaravone, diuretics, and nonsteroidal anti-inflammatory drugs caused acute kidney injury in an elderly patient with chronic kidney disease.

Authors:  Guang Jian Liu; Yun Fu Wang; Yan Jun Zeng; Li Ding; Guo Jun Luo; Li Ping Zhang; Jian'e Zhang
Journal:  CEN Case Rep       Date:  2012-06-08

2.  Pharmacotherapy Pearls for Emergency Neurological Life Support.

Authors:  Gretchen M Brophy; Theresa Human
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

Review 3.  Hyperosmolar therapy for intracranial hypertension.

Authors:  Andrew Torre-Healy; Nicholas F Marko; Robert J Weil
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

4.  Management of crush syndrome casualties after disasters.

Authors:  Mehmet Sukru Sever; Raymond Vanholder
Journal:  Rambam Maimonides Med J       Date:  2011-04-30

Review 5.  Emergency Neurological Life Support: Pharmacotherapy.

Authors:  Gretchen M Brophy; Theresa Human; Lori Shutter
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.532

Review 6.  Intravascular administration of mannitol for acute kidney injury prevention: a systematic review and meta-analysis.

Authors:  Bo Yang; Jing Xu; Fengying Xu; Zui Zou; Chaoyang Ye; Changlin Mei; Zhiguo Mao
Journal:  PLoS One       Date:  2014-01-14       Impact factor: 3.240

7.  Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma.

Authors:  Bryan S Lee; Rupa G Juthani; Andrew T Healy; David M Peereboom; Violette M Recinos
Journal:  Surg Neurol Int       Date:  2014-07-16

8.  Renal tubular epithelial cells injury induced by mannitol and its potential mechanism.

Authors:  Jinwan Shi; Jiuzhan Qian; Hui Li; Hongjun Luo; Wenhong Luo; Zhexuan Lin
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

Review 9.  Role of Bicarbonates and Mannitol in Rhabdomyolysis: A Comprehensive Review.

Authors:  Manoj R Somagutta; Sukrut Pagad; Saijanakan Sridharan; Saruja Nanthakumaran; Ashley A Arnold; Vanessa May; Bilal Haider Malik
Journal:  Cureus       Date:  2020-08-14

10.  Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients.

Authors:  Aaron M Cook; G Morgan Jones; Gregory W J Hawryluk; Patrick Mailloux; Diane McLaughlin; Alexander Papangelou; Sophie Samuel; Sheri Tokumaru; Chitra Venkatasubramanian; Christopher Zacko; Lara L Zimmermann; Karen Hirsch; Lori Shutter
Journal:  Neurocrit Care       Date:  2020-06       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.